Continuing Education (CME)
Adult Molecular Tumor Board
Precision Medicine for IDH-Mutant Glioma in the IDH-Inhibitor Era: Not all Grade 3 Tumors are Created Equal
Enduring CME Activity
Activity Launch Date: May 12, 2025
Activity Expiration Date: May 12, 2027
Deadline to Claim Credit and claim Certificate of Participation is: May 12, 2027, at 11:59 pm ET
This activity is provided by the Society for Neuro-Oncology.
Please note, if you participated in the live activity, you are not eligible to claim credit for the enduring activity.
Target Audience
Neuro-oncologists, medical oncologists, neurosurgeons, neurologists, radiation oncologists, radiologists, neuropathologists, physicians/scientists, clinical and laboratory trainees, and allied health professionals
Statement of Need/Program Overview
The treatment paradigm for IDH-mutant glioma is evolving with the recent FDA approval of vorasidenib for the treatment of IDH-mutant glioma. While the inclusion criteria for the landmark INDIGO trial was limited to low grade IDH-mutant gliomas (WHO grade 2 only), tumor grading based on histological criteria in adult-type diffuse glioma remains controversial in the current molecular era. This virtual tumor board aims to provide a nuanced discussion of the management of IDH-mutant glioma to illustrate the spectrum of considerations that can arise in clinical practice. This session will review the role of pathological grading and prognostication using molecular markers in IDH-mutant glioma. The current standard of care for IDH-mutant glioma will be discussed, eliciting debate on future directions in research and clinical trials to answer outstanding questions stemming from the INDIGO study in the post-vorasidenib FDA approval era.
Educational Objectives
After participating in this CME activity, participants should be able to:
- Describe the value of both radiographic and neuropathologic evaluation of IDH mutant glioma in regard to both diagnosis and treatment.
- Discuss treatment approaches and review the emerging role of IDH-inhibitors for newly diagnosed IDH-mutant glioma
- Discuss prognostic factors and risk stratification in IDH-mutant glioma
Program Agenda
Agenda
Physician Accreditation Statement
The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
The Society for Neuro-Oncology designates the enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit, Claim Certificate of Participation
- Register for the enduring activity through the Neuro-Oncology Academy.
- View the entire recording.
- Complete the evaluation and application for credit.
- Download the CME certificate or certificate of participation from "My Learning Dashboard" located on the left-hand side menu bar.
- Cerficiates of credit should be claimed by physicians (MD, DO, MD/PhD).
- Certificates of participation should be claimed by non-physicians.
Activity Expiration Date: May 12, 2027. Deadline to claim CE Credit will be May 12, 2027, at 11:59 pm ET.
Disclosure of Relevant Financial RelationshipsThe Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months . All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology in accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO. To view the list of disclosures,
click here.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
SNO CME Contact Information
For information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Buchanan, RN at
melesa@soc-neuro-onc.org
For techical assistance with claiming CME credit or certificate of participation, please email
academy@soc-neuro-onc.org.
